I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The major changes in thyroid function during pregnancy are an increase in serum thyroxine-binding globulin (TBG) concentrations and stimulation of the thyrotropin (TSH) receptor by human chorionic gonadotropin.\[[@ref1]\] During pregnancy, serum TBG concentrations rise almost 2-fold (estrogen-related increased production and decrease clearance due to TBG sialylation).\[[@ref2][@ref3]\] With due acknowledgement of the methodological issues with free T4 assay during pregnancy, some studies reported a decrease in free T4 during pregnancy, others reported no change or even an increase.\[[@ref1][@ref4][@ref5]\] Because of the changes in thyroid physiology during pregnancy, the guidelines of the American Thyroid Association (ATA) recommended using trimester-specific reference ranges for TSH and method and trimester-specific reference ranges for serum free T4.\[[@ref6]\] Commercial laboratories are supposed to provide these reference ranges, but many do not do this. In one of the largest population-based studies (over 13,000 pregnant women), the reference range (2.5--97.5^th^ percentile) for TSH in the first trimester was 0.08--2.99 mU/L.\[[@ref7][@ref8][@ref9][@ref10]\] This was the basis of the previous ATA recommendation of normal TSH values during pregnancy: first trimester 0.1--2.5, second trimester 0.2--3.0, and third trimester 0.3--3.0. However, more recent studies in pregnant women in Asia, India, and the Netherlands, have demonstrated only a modest reduction in the upper reference limit.\[[@ref11][@ref12][@ref13][@ref14][@ref15]\] A study of 4800 pregnant women in China recently showed that the downward shift in the TSH reference range occurred at weeks 7--12, but the upper reference limit was only reduced from 5.31 to 4.34 mU/L.\[[@ref12]\] Separate data from a recent prospective intervention trial in the United States support this finding.\[[@ref16]\] Analysis of the TSH and free T4 "set-point" in pregnant women showed that reductions in free T4 were observed only when the serum TSH was \>4.8 mU/L. In some cases, this was not statistically different from the nonpregnant state.\[[@ref13][@ref15]\] There is limited availability of trimester-specific reference ranges calculated for most ethnic and racial populations with adequate iodine intake who are free of thyroid autoantibodies. The recent ATA guidelines\[[@ref17]\] recommend using a TSH upper reference range of 4 mU/L when local assessments are not available. This reference limit should generally be applied beginning with the late first trimester, weeks 7--12, with a gradual return toward the nonpregnant range in the 2^nd^ and 3^rd^ trimesters. There are multiple small cross-sectional data from India on trimester-specific values of TSH from the northern and eastern part of India. We sought to pool this information to see if the pooled data from various studies can define normative data and thyroid dysfunction in pregnancy.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

A systematic review was performed to estimate (i) trimester-specific 5^th^--95^th^ centile TSH values (ii) trimester-specific range of free T4 values in normal pregnant Indian women. This report follows a review protocol adhering to current standards for reporting of systematic reviews.\[[@ref18]\]

Eligibility criteria {#sec2-1}
--------------------

We chose to include studies involving thyroid function tests in normal Indian pregnant women. Normal singleton pregnancies were included in this study. The study had to have excluded those with any major comorbid illness including diabetes, hypertension, cardiac ailments, renal, or hepatic disorders and those on medications that can potentially affect thyroid function tests. Studies on women with recurrent miscarriages and infertility were excluded from the study. The chosen studies had to exclude women with history of thyroid disorder, medications for hypothyroid or hyperthyroidism, family history of thyroid dysfunction, and presence of goiter. Studies with prespecified cutoffs for diagnosis of hypothyroidism were excluded from the study.

Search strategy {#sec2-2}
---------------

The search strategy aimed to find both published and unpublished studies. A comprehensive search from each database\'s inception to March 2017 was conducted with no language restrictions. The databases included Ovid MEDLINE In-process and Other Nonindexed Citations, Ovid MEDLINE, CINNAHL, the Cochrane Controlled Trials Register, Ovid EMBASE, Web of Science, and Scopus. An initial limited search of these databases was undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe article. A second search using all identified keywords and index terms was then undertaken across all included databases. Thirdly, the reference list of all identified reports and articles was searched for additional studies.

Keywords used for database search {#sec2-3}
---------------------------------

The following key words were used primarily to search the database which include thyroid\*, hyperthyr\*, hypothyr\*, tpo\*, tsh, thyrotropin recep-tor antibod\*, thyroid stimulating immunoglobulin\*, thyrotropin-binding inhibit\*, thyroxine, thyrotropin, thyroid microsomal antibodies, fertility, infertility, abortion\*, miscarriag\*, pregnan\*, obstetric\*, gestation \* preterm deliver\*, premature deliver\*, intrauterine growth retardation\*, fetal growth restriction\*, intrauterine growth restriction\* and child development\*. MESH terms including thyroid gland, thyroid diseases immunoglobulins, thyroid-stimulating, thyrotropin, thyroxine, fertility, infertility, pregnancy pregnancy outcome, pregnancy complications, fetal growth retardation and child development were used for the search. The results were then filtered to only include those done in Indian women.

Study identification {#sec2-4}
--------------------

Titles and subsequently abstracts of the articles were screened by two reviewers independently (SK and SM). Included articles for full-text screening were compared during a consensus meeting. In case of disagreement, a third reviewer (AS) was consulted for the decision on inclusion or exclusion for full-text evaluation. Articles that did not contribute to the answer of our research questions after full text evaluation were excluded. Only articles that described at least ten patients were eligible. Articles that did not report concentrations of TSH and/or free T4, and articles on thyroid antibodies in noneuthyroid populations were excluded. After consensus, the remaining articles were included for critical appraisal and assessed by two reviewers independently (SK and SM). Articles were judged on scientific quality according to the CONSORT\[[@ref11][@ref19]\] and STROBE\[[@ref12]\] statement.

Data extraction {#sec2-5}
---------------

Reviewers worked independently and in duplicate using a standardized web-based form collected the following information from each eligible study: (i) Year and Place where the study was conducted (ii) number of pregnant women studied in each trimester and their mean (standard deviation \[SD\]) age (iii) type of study (cross-sectional or longitudinal) and its exclusion criteria described in the study (iv) methodology of thyroid function tests done (v) mean, SD, median, range, 5^th--^ 95^th^ centile of TSH and T4 and/or free T4 in each study (vi) adequacy of Iodine intake assessed by urinary iodine studies (vii) outcome of pregnancy if mentioned.

Data analysis {#sec2-6}
-------------

All results were subject to double data entry. The mean, SD, median and range were calculated for continuous variables. Where statistical pooling was not possible the findings are presented in narrative form including tables and figures to aid in data presentation.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Search results {#sec2-7}
--------------

Out of 56 search results, nine studies were selected based on our objectives. Among the 9 studies, 8 studies were considered for review and data extraction. One was excluded in view of poor quality. Sevens studies are published manuscripts\[[@ref13][@ref14][@ref15][@ref16][@ref20][@ref21][@ref22]\] while one study was poster at an endocrine conference (Choudhary *et al*.) \[[Table 1](#T1){ref-type="table"}\]. The detail of the study selection was described in [Figure 1](#F1){ref-type="fig"}.

###### 

Pooled data of selected studies
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![Selection of studies](IJEM-22-7-g002){#F1}

Study types {#sec2-8}
-----------

Among the eight selected studies seven were cross-sectional and one was longitudinal study.

Laboratory methods {#sec2-9}
------------------

TSH was measured by different assay methods which include electrochemiluminescence,\[[@ref13][@ref15][@ref20]\] enzyme-linked immunosorbent assay,\[[@ref14]\] enzyme immunoassay,\[[@ref21]\] and chemiluminescence immunoassays.\[[@ref16][@ref22]\]

R[ESULTS]{.smallcaps} {#sec1-4}
=====================

We reviewed eight studies for trimester-specific TSH levels in normal Indian pregnant women. A total of 2703 pregnant woman were studied in the selected 8 studies out of which 966, 1072, and 1037 women were tested for TSH levels during first, second, and third, trimesters, respectively. Most of these studies were performed in the Northern and Eastern part of India. None of these studies followed up till the outcome of pregnancy. The exclusion criteria in all studies included those with historical/clinical evidence of thyroid dysfunction, those with family history of thyroid dysfunction, infertility and those with history of recurrent miscarriages (usually \>3). Ultrasound evidence of thyroid disease, urinary iodine assessment, and thyroid antibodies were included as additional exclusion criteria in two, three, and four studies, respectively \[Supplementary file 1\]. While six studies mentioned the mean (SD) TSH and fT4 levels \[[Table 2](#T2){ref-type="table"}\], only four studies reported median TSH values with interquartile range \[[Table 3](#T3){ref-type="table"}\]. Out of the seven studies which reported fT4/T4 levels, six studies checked the free thyroxine (FT4) values while one reported total T4 levels. All the FT4 values are converted into pmol/L and presented in [Table 4](#T4){ref-type="table"}. As part of the pooled data analysis, the 5^th^--95^th^ centile values of normal TSH levels were 0.09--6.65 IU/mL during the first trimester \[[Figure 2](#F2){ref-type="fig"}\], 0.39--6.61 IU/mL during the second trimester \[[Figure 3](#F3){ref-type="fig"}\], and 0.70--5.18 IU/mL during the third trimester \[[Figure 4](#F4){ref-type="fig"}\]. The FT4 levels (5^th^--95^th^ centile values) were 8.24--25.74 pmol/L in first trimester, 6.82--26.0 pmol/L and 5.18--25.61 pmol/L in the third trimester.

###### 

Trimester-specific mean thyroid-stimulating hormone values from selected studies
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Trimester-specific median thyroid-stimulating hormone values from selected studies
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###### 

Trimester-specific free thyroxine values
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![Extent of TSH (5^th^--95^th^ centiles) during the first trimester across various studies](IJEM-22-7-g006){#F2}

![Extent of TSH (5^th^--95^th^ centile) during the second trimester across various studies](IJEM-22-7-g007){#F3}

![Extent of TSH (5^th^--95^th^ centiles) during the third trimester across various studies](IJEM-22-7-g008){#F4}

D[ISCUSSION]{.smallcaps} {#sec1-5}
========================

Although there is considerable heterogeneity in the exclusion criteria in the included studies, only the study from Marwaha *et al*. had a comprehensive exclusion criteria including clinical, sonographical and serological thyroid peroxidase antibodies and anti-Tg (TPO and anti-Tg).\[[@ref13]\] However, it does come as a surprise when the range of TSH reaches up to 10 in some individuals in their study. One of the biggest limitation of the studies conducted have been lack of follow-up of the studied cohort to get details on their pregnancy outcomes. In one of the few outcome studies related to thyroid function, Nambiar *et al*. studied a cohort of 483 consecutive pregnant women in the first trimester and followed them till delivery.\[[@ref23]\] Subjects were prespecified classified as TSH \<2 μIU/mL and TPOAb negative (Group 1) TPOAb positive (Group 2), patients with TSH 2--4 μIU/mL and TPOAb negative (Group 3) TPOAb positive (Group 4) and TSH \>4 μIU/mL (Group 5). Those with TPOAb positivity and TSH \>4 μIU/mL were treated with thyroxine. A TSH \>4 μIU/mL and TPOAb positivity were associated with increased rates of miscarriages. In another study of outcomes in patients with preeclampsia, mean (SD) TSH levels significantly different among those with normal blood pressure: TSH 2 (1.18), those with mild preeclampsia: 3.42 (1.61) mIU/L, and in those with severe preeclampsia 5.63 (2.37). Those with preeclampsia and higher TSH levels had higher risk of low birth weight.\[[@ref24]\]

From the above discussion, it seems safe to diagnose thyroid dysfunction once TSH starts crossing 4.5--5 mIU/L which is the typical cutoff in nonpregnant state. It is important to understand that this is valid in those with proper exclusion criteria particularly those with negative antibodies. Hence, if a clinician decides not to treat a TSH levels between 3 and 5, it is important to make sure the anti-thyroid antibody (TPOAb and/or anti-Tg) is negative. More outcome-based studies are required to know the normative data on antibody positive and antibody negative patients. Studies from outhern and western part of India are also needed to see if there are any regional variations in thyroid functions.

C[ONCLUSIONS]{.smallcaps} {#sec1-6}
=========================

With due limitations imposed by the quality of the available studies, the current review suggests that upper normal limit of TSH values can extend up to 5--6 IU/mL in pregnancy and one can possibly use nonpregnant cutoffs for TSH to diagnose thyroid dysfunction in pregnancy provided appropriate exclusion criteria are met. These results also are closely in line with the recommendations from the recent ATA guidelines for diagnosis of hypothyroidism in pregnancy.
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